Nebulized treprostinil (Tyvaso) reduced lung function decline from idiopathic pulmonary fibrosis (IPF) in the pivotal TETON-1 trial, mirroring positive results from the parallel TETON-2 trial.
Declines from baseline to week 52 for the primary endpoint of median change in forced vital capacity (FVC) came out significantly smaller with multiple daily doses of the prostacyclin vasodilator compared with placebo (-43.3 vs -196.2 mL, P<0.001), Steven Nathan, MD, of Inova Fairfax Hospital in Falls Church, Virginia, reported at the American Thoracic Society (ATS) annual meeting in Orlando. The findings were published simultaneously in the New England Journal of Medicine.
The findings of TETON-1, conducted in the U.S. and Canada, appeared somewhat more impressive than of the similarly designed TETON-2 trial done outside North America. When the two trials were pooled, the between-group difference in FVC from baseline to week 52 favored treprostinil by 111.8 mL (95% CI 79.7-144.0, P<0.0001).
Along with the recent nerandomilast (Jascayd) approval, the new findings come as "a sigh of relief" for the pulmonary community, said ATS session study discussant Darren Taichman, MD, PhD, an editor at the NEJM.
